Caroline S.
- Country
- France
- Department
- Hematology
Research Overview
- Phase 3 Randomized, Double-Blind Study of Brentuximab Vedotin, Lenalidomide, and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Minimal Residual Disease-Adapted Strategy in Multiple Myeloma: Evaluation of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients
- Phase Ib-II Evaluation of Tazemetostat with R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma Patients
Data & Insights
Has run more than one trial at 37 of 103 partner sites.
Specializations
Lymphoma Research
This investigator specializes in the treatment of various lymphoma subtypes, with particular focus on Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Their research encompasses both newly diagnosed cases and relapsed/refractory disease states.
- Novel therapeutic combinations for DLBCL
- High-risk Follicular Lymphoma management
- CD30-positive lymphoma treatments
The investigator explores innovative treatment approaches incorporating targeted therapies such as brentuximab vedotin and tazemetostat in combination with standard therapeutic regimens.
Leukemia Studies
The investigator conducts research in Chronic Lymphocytic Leukemia (CLL), focusing on treatment approaches for previously untreated patients without specific genetic mutations.
- Novel combination therapies
- Minimal residual disease assessment
- Treatment optimization for fit CLL patients
Their work involves evaluating innovative therapeutic combinations including venetoclax and obinutuzumab compared to conventional treatment regimens.
Treatment Innovation
The investigator's research portfolio demonstrates expertise in developing and evaluating targeted therapeutic approaches for hematologic malignancies.
- Response rate optimization
- Novel drug combinations
- Treatment resistance strategies
Their work encompasses the evaluation of progression-free survival and treatment responses across various therapeutic combinations in both first-line and relapsed settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.